“Efficacy and Safety of Teclistamab Followed by Autologous Stem Cells Transplant in Functional High-Risk and Triple Class Refractory Multiple Myeloma”. Mediterranean Journal of Hematology and Infectious Diseases, vol. 17, no. 1, June 2025, p. e2025051, https://doi.org/10.4084/MJHID.2025.051.